Article
Genetics & Heredity
Yalun Li, Gang Chen, Kun Zhang, Jianqiao Cao, Huishan Zhao, Yizi Cong, Guangdong Qiao
Summary: This study used bioinformatic methods to predict breast cancer by selecting therapy genes and possible biomarkers. It identified differentially expressed genes associated with survival and confirmed three hub genes (EZH2, CCNB1, and PPARG) as potential prognostic biomarkers and therapeutic targets for breast cancer.
FRONTIERS IN GENETICS
(2023)
Article
Surgery
Gang Chen, Yalun Li, Jianqiao Cao, Yuanping Dai, Yizi Cong, Guangdong Qiao
Summary: In this study, a circRNA-mediated ceRNA network related to breast cancer (BC) was constructed, and several survival-related genes were detected. This network provides new insight into discovering potential biomarkers for diagnosing and treating BC.
FRONTIERS IN SURGERY
(2023)
Article
Biochemistry & Molecular Biology
Paula Lucia Farre, Rocio Belen Duca, Cintia Massillo, Guillermo Nicolas Dalton, Karen Daniela Grana, Kevin Gardner, Ezequiel Lacunza, Adriana De Siervi
Summary: Breast cancer is the leading cause of death by cancer in women globally. A miRNA signature deregulated in preclinical and clinical BCa models was identified for potential biomarker discovery, useful for BCa diagnosis and/or prognosis. Certain miRNAs were up-regulated and down-regulated in BCa, showing negative correlation with the expression of related genes. Genes such as GAB1, GNG12, HBP1, and SESN1 have been found to have expression levels related to patient survival in aggressive BCa subtypes.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Biochemistry & Molecular Biology
Shasha Tang, Wenjing Liu, Liyun Yong, Dongyang Liu, Xiaoyan Lin, Yuan Huang, Hui Wang, Fengfeng Cai
Summary: KRT17 expression is closely associated with prognosis in breast cancer, especially in patients with high HER2 expression. KRT17 may be involved in multiple immune pathways and associated with various immune cells. This finding provides a promising biomarker for the diagnosis and prognosis of breast cancer.
Article
Immunology
Xiangyu Sun, Xin Fu, Shouping Xu, Pengfei Qiu, Zhidong Lv, Mingke Cui, Qiang Zhang, Yingying Xu
Summary: This study investigated the expression of OLR1 in breast cancer tissues and its correlation with clinical outcomes, finding that OLR1 upregulation was associated with worse prognosis and tumor infiltration. Additionally, OLR1 may regulate immunity-related pathways, particularly macrophage polarization, affecting the survival of breast cancer patients.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Immunology
Qing Peng, Tingyu Wen, Dongyang Liu, Suguo Wang, Xinting Jiang, Shiju Zhao, Gaozhong Huang
Summary: This study comprehensively analyzed DSN1 expression in different molecular subtypes or stages of breast cancer, and found that upregulation of DSN1 was strongly associated with poor prognosis and decreased survival in breast cancer. Significant differences in DSN1 expression were also observed in different pathological subtypes and stages of breast cancer.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Oncology
Subhash Chand, Vikrant Mehta, Ratnesh K. Sharma, Anupkumar R. Anvikar, Harish Chander
Summary: Breast cancer, the most commonly diagnosed cancer worldwide, has a poor prognosis. This study found that CHAC2 expression was elevated in breast cancer patients and was associated with lower overall survival. These findings suggest that CHAC2 may be an important biomarker and have potential therapeutic implications in breast cancer.
FRONTIERS IN ONCOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Hsing-Ju Wu, Pei-Yi Chu
Summary: Breast cancer is the most commonly diagnosed cancer type in women worldwide and has six molecular subtypes. Early detection and screening are crucial for improving therapeutic outcomes, requiring reliable noninvasive diagnostic and prognostic biomarkers.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Genetics & Heredity
Zhijian Huang, Chen Xiao, Fushou Zhang, Zhifeng Zhou, Liang Yu, Changsheng Ye, Weiwei Huang, Nani Li
Summary: A novel immune-associated lncRNA signature was successfully constructed to accurately predict the prognosis of breast cancer. The signature was significantly correlated with the infiltration of immune cells, showing its potential as an important prognostic factor and independent prognostic marker.
FRONTIERS IN GENETICS
(2021)
Article
Pathology
Jelena Milovanovic, Natasa Todorovic-Rakovic, Tijana Vujasinovic, John Greenman, Vesna Mandusic, Marko Radulovic
Summary: This study evaluated the prognostic value of intratumoral granulysin (GNLY) and its association with clinicopathological parameters in breast cancer patients. The results showed a significant correlation between GNLY levels and cancer recurrence, with high levels indicating a low risk of local recurrence but a high risk of distant metastasis.
PATHOLOGY RESEARCH AND PRACTICE
(2022)
Article
Oncology
Xiaomei Zhou, Qu Zhang, Gai Liang, Xinjun Liang, Bo Luo
Summary: This study examined the prognostic significance of HMGB3 in breast cancer by analyzing its expression levels, mutation status, coexpression, and immune correlation in multiple databases. The results showed that high expression of HMGB3 was associated with poor overall survival and increased immunological infiltration in breast cancer patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
F. Lerebours, S. Vacher, J. M. Guinebretiere, S. Rondeau, M. Caly, D. Gentien, S. Van Laere, F. Bertucci, P. de la Grange, L. Bieche, X. Liang, C. Callens
Summary: This study identified a 5-splice signature that can distinguish IBC from non-IBC tumors, as well as confirmed overexpression of hemoglobin genes in IBC. These findings provide important clues for further functional studies.
JOURNAL OF ADVANCED RESEARCH
(2021)
Article
Medicine, Research & Experimental
Jialiang Zheng, Fenglin Miao, Zhao Wang, Yuan Ma, Zhenhang Lin, Yaqin Chen, Xu Kong, Yue Wang, Aobo Zhuang, Ting Wu, Wengang Li
Summary: This study conducted a comprehensive analysis of the role of MDM2 in human cancer and found that MDM2 is a reliable prognostic biomarker closely related to cancer immunity, providing a potential immunotherapeutic target for breast cancer, bladder cancer, and ovarian cancer.
Article
Oncology
Min Wu, Pan Zhang, Penghui Wang, Zhen Fang, Yaqin Zhu
Summary: The study identified FEN1 as a potential diagnostic and prognostic marker for breast cancer through ELISA and ECLIA analysis, showing significantly higher expression in BC patients. FEN1 demonstrated higher diagnostic accuracy compared to CA153 and CEA, and was closely associated with breast cancer staging and survival prognosis.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Xiaojun Zhang, Mengke Niu, Tianye Li, Yuze Wu, Jinnan Gao, Ming Yi, Kongming Wu
Summary: S100A8/A9 is significantly increased in basal-like and Her2-overexpressed subtypes of breast cancer, predicting poor prognosis. The tumor suppressor DACH1 inhibits the expression of S100A8/A9. The combination of S100A8/A9 and DACH1 predicts the overall survival of breast cancer patients more accurately.
BIOMARKER RESEARCH
(2023)